The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Open accessAbstract
Background No medication is currently approved for the treatment of cocaine dependence, but several preclinical and clinical reports suggest agonist-like medications, e.g., amphetamine analogues, may be a productive strategy for medication development. Objective This current proof-of-concept study sought to evaluate the safety, tolerability, and effectiveness of methamphetamine as a candidate treatment for cocaine dependence. Methods A randomized, double-blind, placebo-controlled study served to evaluate three treatment conditions in 82 cocaine-dependent individuals: (1) placebo (0mg, 6x/day; n=27), (2) immediate release (IR) methamphetamine (5mg, 6x/day; n=30), (3) sustained release (SR) methamphetamine (30 mg first pill, 1x/day; 0mg 5x/day; n=25). The study employed a sequential, two-phase design (i.e., 4 weeks of medication and counseling followed by 4 weeks of medication/counseling plus a contingency management procedure). Results Both preparation forms of methamphetamine were well-tolerated, with similar retention to placebo (0mg, 33%; 30 mg IR, 30%, 30 mg SR, 32%). Methamphetamine SR was associated with decreased sleep and increased weight loss. Medication adherence rates were high for the first dose of the day (95%), while adherence for subsequent capsules was lower. Those in the SR condition exhibited consistently lower rates of cocaine-positive urine samples (0mg, 60%; 30 mg IR, 66%; 30 mg SR, 29%), p<0.0001, and reported the greatest reduction in craving for cocaine, p<0.05. Conclusions SR methamphetamine significantly reduced cocaine use and craving. Additional research is warranted to develop and evaluate agonist-like medications that may effectively treat cocaine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among patients with lifetime ATS use disorder, 29.3% reported four or more ACEs, 28.7% reported two to three ACEs, 21.6% reported one ACE, and 20.4% reported no ACEs.250”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [250]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Elsevier eBooks · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,168
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Babor, T. F. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080007002 · Cited by 903
A behavioral approach to achieving initial cocaine abstinence
Higgins, S. T., Delaney, D. D., Budney, A. J., Bickel, W. K., Hughes, J. R., Foerg, F. E., & Fenwick, J. W. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.9.1218 · Cited by 553
The need for speed: an update on methamphetamine addiction
Barr, A. M., Panenka, W. J., MacEwan, G. W., Thornton, A. E., Lang, D. J., Honer, W. G., & Lecomte, T. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0635 · Cited by 441
Cited by
Sorted by citations
Items 101–125 of 125
Blood Pressure, HIV, and Cocaine Use Among Ethnically and Racially Diverse Individuals
Soni, M., Rodriguez, V. J., Babayigit, S., Jones, D. L., & Kumar, M. (2018) · Southern Medical Journal · doi:10.14423/smj.0000000000000893 · Cited by 3
Turpin, M. A. C., Rowland, K. C., Anugwom, C., Arocha, M., Carona, A., Gonzalez, B. I., Iskander, G., Snyder, S., Wilson, K., Kaye, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98814-8.00027-5 · Cited by 3
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3
Sinatora, A. B., Chiloff, D., Santos, J. P. M., Xu, K. Y., Tardelli, V., & Fidalgo, T. (2025) · Substance use & addiction journal · doi:10.1177/29767342251326374 · Cited by 3
Zhaleh, H., Ridha, A. A., & Amini, K. (2020) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2020_034 · Cited by 1
Brandt, L., Chao, T. W.-C., Comer, S. D., & LEVIN, F. R. (2021) · Addiction · doi:10.1111/add.15423 · Cited by 1
Neurochemical Imaging in Addiction
Wai, J. M., LEVIN, F. R., & Martínez, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00001-8 · Cited by 1
Treating Cocaine Dependency with Psychopharmacotherapy and Behavioral Therapy
Liebman, R. (2014) · Cited by 1
Evidence-based pharmacotherapy of illicit substance use disorders
van den Brink, W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.013
García, Y. Á. (2015) · TDX (Tesis Doctorals en Xarxa)
Agonist-Like (Substitution) Treatment for Cocaine and Other Stimulant Dependence
Grabowski, J. G., Mooney, M. E., & Herin, D. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00047-6
Self-citationCocaïne et méthylphénidate : quelques données épidémiologiques
Roux, P. (2015) · Psychotropes · doi:10.3917/psyt.214.0041
Nuijten, M. (2017) · Data Archiving and Networked Services (DANS)
Clauss, N. J., & Daws, L. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00172-9
Milios, A. (2022) · Dalhousie Medical Journal · doi:10.15273/dmj.vol48no1.11259
Gálligo, F. C., Fernández, I. G., & Majada, A. C. (2010) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(10)70002-5
Attention Deficit/Hyperactivity Disorder and Substance Abuse
Levin, F. (2015) · Springer eBooks · doi:10.1007/978-88-470-5322-9_119
Disorders Due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_26-1
Marie, N., & Noble, F. (2024) · Psychotropes · doi:10.3917/psyt.294.0105
Chapter 54. Treatment of Substance Use Disorders
Sherman, B. J., Hartwell, K. J., McRae‐Clark, A. L., Herron, A., & Brady, K. T. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as54
Kampman, K. M. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg06
Paterson, C., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R., Webster, K. E., Spiga, F., Dawson, S., et al. (2025) · medRxiv · doi:10.64898/2025.12.10.25341965
Bourtin, I. G., Calvillo, D. J., Badawi, J. C., Schmitz, J. M., Lane, S. D., Yoon, J. H., & Webber, H. E. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113125
Self-citationPaterson, C. A., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R. J., Webster, K. E., Spiga, F., Dawson, S., et al. (2026) · Addiction · doi:10.1111/add.70486
BindingDB Entry 50044678: Alpha-ethyltryptamines as dual dopamine-serotonin releasers.
BindingDB (2016) · UC San Diego · doi:10.7270/q2416znk
Metadata
- Authors
- Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Mooney, Marc E.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 101
- Issue
- 1-2
- Pages
- 34-41
- ISSN
- 0376-8716 (ISSN-L)
- PMC
- PMC2742691
- OpenAlex
- W2008441751
- Cited by
- 124
- References
- 54
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 3 · 2016: 13 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 14
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p50da009262-20)
- National Institute on Drug Abuse (#P50 DA009262, R01DA016305, R00DA023548, K99DA023548, P50DA09262, L30 DA023817, R01-DA16305, K01DA019446, K01-DA-023548)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- cocaine dependence, methamphetamine, cocaine craving, sustained-release formulation, medication adherence, contingency management, treatment retention, drug use reduction, sleep reduction, weight loss
- MeSH terms
- Adolescent, Adult, Affect, Central Nervous System Stimulants, Blood Pressure, Body Weight, Delayed-Action Preparations, Double-Blind Method, Female, Heart Rate, Humans, Male, Methamphetamine, Middle Aged, Riboflavin, Substance Abuse Detection, Treatment Outcome, Cocaine-Related Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
